Carmine Therapeutics was established by EVX Ventures and 3 scientific cofounders including myself, Prof. Harvey Lodish (MIT), and Prof. Jiahai Shi (City University of Hong Kong) in 2019. With a granted patent, Carmine is the first company in the world to harness RBCEVs as vehicles for gene therapy. By leveraging the unique properties of red blood cell extracellular vesicles (RBCEVs), we are developing the REGENT platform for next-generation non-viral gene therapies that overcome the current limitations of viral-based gene therapies such as immunogenicity, small transgene capacity, and manufacturing challenges. Since the establishment in Singapore, we have received a Golden ticket from Bristol Myers Squibb and relocated our headquarter to Boston. In 2020, Carmine entered a $900 million collaboration with Takeda, a global pharmaceutical company, to develop gene therapy for rare diseases. Carmine also received the Fierce-15 award as one of the top biotech start-up companies.